IP Library Granted Patent US 8,822,477
Granted Patent B2
US 8,822,477 · App. 10/563,586 · Granted Sep 2, 2014

Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis

Inventor: Jean Krutmann (Wegberg, DE)
Assignee: Bitop AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,822,477
App. No.
10/563,586
Granted
Sep 2, 2014
Kind
B2
Abstract

The invention relates to the use of osmolytes, in particular ectoine and hydroxyectoine, as well as their pharmacologically compatible salts and/or derivatives having equivalent effects, for producing dermatological preparations such as tinctures, lotions, O/W emulsions, W/O emulsions, creams, ointments, hydrogels or sprays for the topical prophylaxis, care and/or treatment of neurodermatitis.

Claims (9)

1. A method of treating neurodermatitis patients comprising topical application on affected skin of a dermatological preparation comprising an osmolyte or a pharmacologically compatible salt thereof to a patient in need thereof, wherein the osmolyte is ectoine or hydroxyectoine or a pharmacologically compatible salt thereof, wherein said osmolyte results in accelerated healing of the affected skin.

2. The method of claim 1 , wherein the dermatological preparation is a tincture, lotion, O/W emulsion, W/O emulsion, cream, ointment or a hydrogel or spray comprising auxiliary substances.

3. The method of claim 2 , wherein the dermatological preparation is an ointment, cream or lotion, comprising liposomes containing the osmolyte.

4. The method of claim 3 , wherein the dermatological preparation is an ointment, cream or lotion containing the osmolyte liposomally capsuled.

5. The method of claim 1 , wherein the dermatological preparation contains additional active agents.

6. The method of claim 5 , wherein the dermatological preparation contains an active agent selected from analgetics, antiphlogistics, antipruritic substances, antibiotics, fungistats and fungicides.

7. The method of claim 5 or 6 , wherein the additional active agent is a calcineurin inhibitor.

8. The method of claim 1 , wherein the dermatological preparation consists essentially of ectoine or hydroxyectoine or a pharmacologically compatible salt thereof.

9. The method of claim 1 , wherein the dermatological preparation comprises ectoine or hydroxyectoine or a pharmacologically compatible salt thereof in the absence of a glucocorticoid.

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Jul 16, 2014
From: BITOP AKTIENGESELLSCHAFT FUR BIOTECHNISCHE OPTIMIERUNG; BITOP AG
To: BITOP AG
Reel/Frame 033347/0088 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT SPELLING OF ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 018642 FRAME 0728. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT TO BITOP AKTIENGESELLSCHAFT FUR BIOTECHNISCHE OPTIMIERUNG. Recorded May 14, 2014
From: KRUTMANN, JEAN
To: BITOP AKTIENGESELLSCHAFT FUR BIOTECHNISCHE OPTIMIERUNG
Reel/Frame 032895/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2006
From: KRUTMANN, JEAN
To: BITOP ATKIENGESELLSCHAFT FUR BIOTECHNICHE OPTIMIERUNG
Reel/Frame 018642/0728 →
Priority Claims (1)
DE 103 30 243 · Jul 3, 2003 · national
Continuity (1)
Related Publication 20070122464A1 · May 31, 2007